Cargando…
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry
INTRODUCTION: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach cat...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245192/ https://www.ncbi.nlm.nih.gov/pubmed/34737227 http://dx.doi.org/10.1183/13993003.02419-2021 |
_version_ | 1784738694444351488 |
---|---|
author | Boucly, Athénaïs Weatherald, Jason Savale, Laurent de Groote, Pascal Cottin, Vincent Prévot, Grégoire Chaouat, Ari Picard, François Horeau-Langlard, Delphine Bourdin, Arnaud Jutant, Etienne-Marie Beurnier, Antoine Jevnikar, Mitja Jaïs, Xavier Simonneau, Gérald Montani, David Sitbon, Olivier Humbert, Marc |
author_facet | Boucly, Athénaïs Weatherald, Jason Savale, Laurent de Groote, Pascal Cottin, Vincent Prévot, Grégoire Chaouat, Ari Picard, François Horeau-Langlard, Delphine Bourdin, Arnaud Jutant, Etienne-Marie Beurnier, Antoine Jevnikar, Mitja Jaïs, Xavier Simonneau, Gérald Montani, David Sitbon, Olivier Humbert, Marc |
author_sort | Boucly, Athénaïs |
collection | PubMed |
description | INTRODUCTION: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators. METHODS: We evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan–Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches. RESULTS: At baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk. CONCLUSIONS: The four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach. |
format | Online Article Text |
id | pubmed-9245192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-92451922022-07-01 External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry Boucly, Athénaïs Weatherald, Jason Savale, Laurent de Groote, Pascal Cottin, Vincent Prévot, Grégoire Chaouat, Ari Picard, François Horeau-Langlard, Delphine Bourdin, Arnaud Jutant, Etienne-Marie Beurnier, Antoine Jevnikar, Mitja Jaïs, Xavier Simonneau, Gérald Montani, David Sitbon, Olivier Humbert, Marc Eur Respir J Original Research Articles INTRODUCTION: Contemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators. METHODS: We evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan–Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches. RESULTS: At baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk. CONCLUSIONS: The four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach. European Respiratory Society 2022-06-30 /pmc/articles/PMC9245192/ /pubmed/34737227 http://dx.doi.org/10.1183/13993003.02419-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Original Research Articles Boucly, Athénaïs Weatherald, Jason Savale, Laurent de Groote, Pascal Cottin, Vincent Prévot, Grégoire Chaouat, Ari Picard, François Horeau-Langlard, Delphine Bourdin, Arnaud Jutant, Etienne-Marie Beurnier, Antoine Jevnikar, Mitja Jaïs, Xavier Simonneau, Gérald Montani, David Sitbon, Olivier Humbert, Marc External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry |
title | External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry |
title_full | External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry |
title_fullStr | External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry |
title_full_unstemmed | External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry |
title_short | External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry |
title_sort | external validation of a refined four-stratum risk assessment score from the french pulmonary hypertension registry |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245192/ https://www.ncbi.nlm.nih.gov/pubmed/34737227 http://dx.doi.org/10.1183/13993003.02419-2021 |
work_keys_str_mv | AT bouclyathenais externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT weatheraldjason externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT savalelaurent externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT degrootepascal externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT cottinvincent externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT prevotgregoire externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT chaouatari externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT picardfrancois externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT horeaulanglarddelphine externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT bourdinarnaud externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT jutantetiennemarie externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT beurnierantoine externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT jevnikarmitja externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT jaisxavier externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT simonneaugerald externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT montanidavid externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT sitbonolivier externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry AT humbertmarc externalvalidationofarefinedfourstratumriskassessmentscorefromthefrenchpulmonaryhypertensionregistry |